These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6004582)

  • 1. Is brain damage the cause of "pink spot"?
    Nunn RF; Wheeler RH
    Nature; 1966 Nov; 212(5065):939. PubMed ID: 6004582
    [No Abstract]   [Full Text] [Related]  

  • 2. Schizophrenia and pink spot.
    Stam FC; Heslinga FJ; van Tilburg W
    Psychiatr Neurol Neurochir; 1969; 72(6):513-24. PubMed ID: 5369242
    [No Abstract]   [Full Text] [Related]  

  • 3. Identity of a urinary "pink spot" in schizophrenia and Parkinson's disease.
    Boulton AA; Pollitt RJ; Majer JR
    Nature; 1967 Jul; 215(5097):132-4. PubMed ID: 6049100
    [No Abstract]   [Full Text] [Related]  

  • 4. The "pink spot", 3,4-dimethoxyphenylethylamine and dopamine. Relationship to Parkinson's disease and to schizophrenia.
    Barbeau A
    Rev Can Biol; 1967 Mar; 26(1):55-79. PubMed ID: 4865100
    [No Abstract]   [Full Text] [Related]  

  • 5. [Significance and identification of 3,4-dimethoxyphenylethylamine in the urine of schizophrenic patients (pink spot reaction)].
    Stanciu E; Csiky K; Rácz E
    Neurol Psihiatr Neurochir; 1971; 16(4):305-12. PubMed ID: 5118389
    [No Abstract]   [Full Text] [Related]  

  • 6. The "pink spot" in schizophrenics and its absence in homocystinurics.
    Welch JP; Clower CG; Schimke RN
    Br J Psychiatry; 1969 Feb; 115(519):163-7. PubMed ID: 5778193
    [No Abstract]   [Full Text] [Related]  

  • 7. The "pink spot," 3,4-dimethoxyphenylethylamine, common tea, and schizophrenia.
    Stabenau JR; Creveling CR; Daly J
    Am J Psychiatry; 1970 Nov; 127(5):611-6. PubMed ID: 5491537
    [No Abstract]   [Full Text] [Related]  

  • 8. [Neurologic and psychic complications in treatment with neuroleptics].
    Gerlach J
    Ugeskr Laeger; 1976 Jun; 138(27):1650-3. PubMed ID: 951778
    [No Abstract]   [Full Text] [Related]  

  • 9. Some observations concerning the "pink spot" reacting substances in urine.
    Watt JA; Ashcroft GW; Daly RJ; Smythies JR
    Acta Psychiatr Scand; 1970; 46(4):374-90. PubMed ID: 5502783
    [No Abstract]   [Full Text] [Related]  

  • 10. Persistent dyskinesia.
    Crane GE
    Br J Psychiatry; 1973 Apr; 122(569):395-405. PubMed ID: 4577946
    [No Abstract]   [Full Text] [Related]  

  • 11. The "pink spot" and schizophrenia.
    Boulton AA; Felton CA
    Nature; 1966 Sep; 211(5056):1404-5. PubMed ID: 5969835
    [No Abstract]   [Full Text] [Related]  

  • 12. Tardive dyskinesia: an evaluation of the etiologic association with neuroleptic therapy.
    Baldessarini RJ
    Can Psychiatr Assoc J; 1974 Dec; 19(6):551-4. PubMed ID: 4613452
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of 3,4-dimethoxyphenethylamine from schizophrenic urine by mass spectrometry.
    Creveling CR; Daly JW
    Nature; 1967 Oct; 216(5111):190-1. PubMed ID: 6057236
    [No Abstract]   [Full Text] [Related]  

  • 14. Identity of the "pink spot".
    Bell CE; Somerville AR
    Nature; 1966 Sep; 211(5056):1405-6. PubMed ID: 5969836
    [No Abstract]   [Full Text] [Related]  

  • 15. The pink spot: a red herring?
    Lancet; 1966 Oct; 2(7468):848-9. PubMed ID: 4162179
    [No Abstract]   [Full Text] [Related]  

  • 16. [Biochemical studies in schizophrenia. On the "pink spot" phenomenon].
    Vogel WH
    Munch Med Wochenschr; 1967 Aug; 109(31):1633-41. PubMed ID: 5631559
    [No Abstract]   [Full Text] [Related]  

  • 17. "Pink spot" and schizophrenia.
    Ridges AP; Bourdillon RE; Leslie SA; Harper P
    Psychiatr Clin (Basel); 1968; 1(1):44-62. PubMed ID: 4880076
    [No Abstract]   [Full Text] [Related]  

  • 18. A pink spot in thyrotoxicosis.
    Widelitz M; Feldman W
    Biol Psychiatry; 1971; 3(2):181-4. PubMed ID: 5089913
    [No Abstract]   [Full Text] [Related]  

  • 19. The metabolism of dimethoxyphenethylamine, a compound found in the urine of schizophrenics.
    Schweitzer JW; Friedhoff AJ
    Am J Psychiatry; 1968 Mar; 124(9):1249-53. PubMed ID: 5637912
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of tardive dyskinesia. 3. Clinical efficacy of a dopamine competing agent, methyldopa.
    Kazamatsuri H; Cole JO
    Arch Gen Psychiatry; 1972 Dec; 27(6):824-7. PubMed ID: 4637899
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.